+241.1%
ALAB vs MRNA
+100.0%
+141.1%
-63.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.6% | -3.9% | +8.5% | +4.8% |
| 7D | -2.1% | -17.6% | +15.4% | -1.1% |
| 30D | -26.0% | -5.1% | -20.8% | -25.6% |
| 3M | -33.9% | +220.8% | -254.7% | -39.3% |
| 6M | -9.1% | +321.7% | -330.8% | -22.6% |
| YTD | +27.2% | +601.3% | -574.1% | -6.2% |
| 1Y | +49.7% | +735.2% | -685.6% | +5.9% |
| All | +241.1% | +100.0% | +141.1% | +196.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling